NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus
NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus
Dow JonesMay 1 12:01 ET
NervGen Pharma GAAP EPS of -$0.38
Seeking AlphaApr 17 11:54 ET
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update
NervGen Pharma Corp. (NGEN.V), a biotech company developing solutions to treat nervous system damage, reported a net loss of $22.4 million, or $(0.38) per basic and diluted share for the year ended De
MT NewswiresApr 17 10:45 ET
NervGen Pharma GAAP EPS of -$0.07
Seeking AlphaNov 9, 2023 12:04 ET
NervGen Pharma GAAP EPS of -$0.08
Seeking AlphaMay 15, 2023 12:27 ET
NervGen Pharma Appoints Michael Kelly as President & CEO
Seeking AlphaApr 10, 2023 09:23 ET
NervGen Pharma GAAP EPS of -$0.39
Seeking AlphaMar 30, 2023 09:39 ET
NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 42% Below Their Intrinsic Value Estimate
Yahoo FinanceJan 6, 2023 06:02 ET
NervGen Grants 400K Stock Options to Directors
Seeking AlphaNov 16, 2022 05:30 ET
NervGen Pharma Reports Q3 Results
Seeking AlphaNov 14, 2022 10:01 ET
NervGen Pharma Awarded up to $1.5M US Department of Defense Funding
NervGen Pharma (OTCQX:NGENF) has been awarded up to $1.5M in US Department of Defense funding from the Military Operational Medicine Research Program to evaluate NervGen's NVG-291-R as a therapeutic t
Seeking AlphaOct 12, 2022 09:04 ET
NervGen Pharma Appoints Bill Radvak as Interim CEO
NervGen Pharma (OTCQX:NGENF) notifies that the board and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & CEO and a member of the board, effective immediately. The
Seeking AlphaSep 23, 2022 03:39 ET
NervGen Pharma GAAP EPS of -$0.13
NervGen Pharma press release (OTCQX:NGENF): Q2 GAAP EPS of -$0.13. Cash position enhanced by over $22M.
Seeking AlphaAug 10, 2022 17:42 ET
NervGen Pharma GAAP EPS of -$0.11
NervGen Pharma press release (OTCQX:NGENF): Q1 GAAP EPS of -$0.11.NervGen had cash and investments of $12.8 million as of March 31, 2022, compared to $5.0 million as of March 31, 2021. The net cash
Seeking AlphaMay 12, 2022 09:05 ET
NervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291
NervGen Pharma (OTCQX:NGENF) received approval from A safety review committee to advance to the second cohort in the multiple ascending dose (MAD) portion of its phase 1 trial of NVG-291. The company
Seeking AlphaMar 15, 2022 15:46 ET
NervGen Pharma Closes $9.2 Million Bought Deal Financing
10:46 AM EST, 11/12/2021 (MT Newswires) -- NervGen Pharma Corp. (NGEN.V), a clinical-stage biotech company, said Friday that it has completed a $9.2 million bought deal financing. This included the f
MT NewswiresNov 12, 2021 12:01 ET
NervGen Pharma Upsizes Bought Deal Financing; Falls 11.1%
01:51 PM EDT, 11/05/2021 (MT Newswires) -- NervGen Pharma Corp., (NGEN.V), a clinical-stage biotech company, said Friday that it has increased the size of its $5 million bought deal offering. Under t
MT NewswiresNov 6, 2021 20:14 ET
Industrial Alliance Initiates Coverage On NervGen Pharma with Speculative Buy Rating, Announces Price Target of $6
Industrial Alliance initiates coverage on NervGen Pharma (OTC:NGENF) with a Speculative Buy rating and announces Price Target of $6.
Benzinga Real-time NewsJul 13, 2021 08:55 ET
NervGen Pharma analyst ratings
DateResearch FirmActionCurrentPT 7/13/21Industrial AllianceInitiates Coverage OnSpeculative Buy6.0
Benzinga Analyst RatingsJul 13, 2021 08:53 ET
No Data
No Data